文献速递乳腺癌消化系统肿瘤胸部肿瘤

针对中危发热性中性粒细胞减少患者使用集落刺激因子的固定医嘱录入干预的实用整群随机试验

A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
PubMed 文献 · J Clin Oncol · 2022-10-13

TrACER整群随机试验的子研究纳入846例接受中危发热性中性粒细胞减少方案的患者,比较固定医嘱录入(SOE)促进预防性集落刺激因子(PP-CSF)使用与提示不使用的效果。SOE组PP-CSF使用率显著更高(37.1% vs 9.9%,OR 5.91,95%CI 1.77-19.70,P=0.0038),但两组发热性中性粒细胞减少发生率低且相同(3.7% vs 3.7%)。作者认为SOE或PP-CSF均不足以证明对所有中危方案患者常规使用的获益。

要点

  • SOE干预使中危方案患者PP-CSF使用率从9.9%升至37.1%(OR 5.91,95%CI 1.77-19.70,P=0.0038)。
  • 两组发热性中性粒细胞减少发生率均为3.7%,无差异。
  • 作者认为SOE或PP-CSF均不足以证明对所有一线中危方案患者使用的获益。

核心结论

  • 尽管SOE干预显著增加了一线中危方案患者的PP-CSF使用,但发热性中性粒细胞减少发生率低且两组无差异。
  • 作者认为SOE或PP-CSF均不足以证明对所有一线中危方案患者常规使用的获益。

研究设计与样本

  • TrACER为实用整群随机试验,实践中心随机接受常规护理或基于指南的SOE干预。
  • 主研究按3:1随机分配中心至高危方案自动PP-CSF医嘱SOE/低危方案反对PP-CSF提示 vs 常规护理。
  • 二次1:1随机分配24个干预中心至中危方案SOE促进处方或提示不处方PP-CSF。
  • 2016年1月至2020年4月注册846例接受中危方案的患者,SOE组12中心542例,提示组12中心304例。
  • 纳入乳腺癌、结直肠癌或非小细胞肺癌患者,允许临床医生覆盖SOE。

主要发现

  • SOE组PP-CSF使用率为37.1%,提示组为9.9%(OR 5.91,95%CI 1.77-19.70,P=0.0038)。
  • SOE组发热性中性粒细胞减少发生率为3.7%,提示组为3.7%,两组相同。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Primary prophylactic colony-stimulating factors (PP-CSFs) are prescribed to reduce febrile neutropenia (FN) but their benefit for intermediate FN risk regimens is uncertain. Within a pragmatic, randomized trial of a standing order entry (SOE) PP-CSF intervention, we conducted a substudy to evaluate the effectiveness of SOE for patients receiving intermediate-risk regimens. METHODS: TrACER was a cluster randomized trial where practices were randomized to usual care or a guideline-based SOE intervention. In the primary study, sites were randomized 3:1 to SOE of automated PP-CSF orders for high FN risk regimens and alerts against PP-CSF use for low-risk regimens versus usual care. A secondary 1:1 randomization assigned 24 intervention sites to either SOE to prescribe or an alert to not prescribe PP-CSF for intermediate-risk regimens. Clinicians were allowed to over-ride the SOE. Patients with breast, colorectal, or non-small-cell lung cancer were enrolled. Mixed-effect logistic regression models were used to test differences between randomized sites. RESULTS: Between January 2016 and April 2020, 846 eligible patients receiving intermediate-risk regimens were registered to either SOE to prescribe (12 sites: n = 542) or an alert to not prescribe PP-CSF (12 sites: n = 304). Rates of PP-CSF use were higher among sites randomized to SOE (37.1% v 9.9%, odds ratio, 5.91; 95% CI, 1.77 to 19.70; P = .0038). Rates of FN were low and identical between arms (3.7% v 3.7%). CONCLUSION: Although implementation of a SOE intervention for PP-CSF significantly increased PP-CSF use among patients receiving first-line intermediate-risk regimens, FN rates were low and did not differ between arms. Although this guideline-informed SOE influenced prescribing, the results suggest that neither SOE nor PP-CSF provides sufficient benefit to justify their use for all patients receiving first-line intermediate-risk regimens.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hershman DL, Bansal A, Sullivan SD, et al. A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia. J Clin Oncol. 2022. PMID: 36228177. doi:10.1200/JCO.22.01258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。